Lifecare Sensor Study Shows Strong High-Glucose Performance in Implantable CGM

Lifecare AS ( (DE:LFC0) ) just unveiled an update.

Lifecare ASA has reported new findings from its ongoing LFC-SEN-002 longevity study in dogs, showing that its implantable, non-enzymatic glucose sensor continues to deliver clear, structured and directional glucose signals even at very high glucose levels where traditional enzyme-based CGM systems tend to lose resolution. The company says the osmotic pressure-based sensing mechanism avoids saturation effects seen in enzyme chemistry, reinforcing confidence in the robustness and scalability of its implantable CGM platform and supporting continued optimisation of long-term stability, preparation for veterinary market entry, and progress toward first-in-human studies and eventual CE marking, with the current data underpinning both veterinary product development and future human clinical programmes.

More about Lifecare AS

Lifecare ASA is a Bergen-based medical sensor company developing next-generation continuous glucose monitoring (CGM) systems using a non-enzymatic, osmotic pressure-based sensing principle. Its technology is designed for long-term implantable sensors capable of monitoring various analytes in humans and pets, with a particular market focus on diabetes management and future veterinary and human clinical applications.

Average Trading Volume: 495,958

Current Market Cap: NOK161.6M

Find detailed analytics on LFC0 stock on TipRanks’ Stock Analysis page.